Cingulate Inc. (NASDAQ: CING) has released Phase 3 safety data for CTx-1301 (dexmethylphenidate), a once-daily stimulant medication designed to provide full-day efficacy for individuals with Attention Deficit Hyperactivity Disorder (ADHD).1,2 The data, which includes results from 2 pediatric and adolescent studies, will support the company’s New Drug Application (NDA) submission to the FDA, expected to be filed with the federal agency in the first half of 2025, according to news releases from Cingulate.